FDA approves Serenity Pharmaceuticals’ Noctiva for nocturnal polyuria
The US Food and Drug Administration has approved Noctiva (desmopressin acetate) developed by Serenity Pharmaceuticals for the treatment of nocturia syndrome in adults.
Serenity Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Noctiva (desmopressin acetate), a nasal spray developed to treat nocturnal polyuria syndrome in adults. This marks a significant milestone as Noctiva becomes the first FDA-approved treatment specifically for nocturnal urine overproduction, commonly known as nocturia syndrome. Groundbreaking Treatment for Nocturnal Polyuria Nocturnal polyuria […]